Impact of Pharmaceutical care on hypothyroid patients with metabolic syndrome
Not Applicable
- Conditions
- Health Condition 1: E039- Hypothyroidism, unspecified
- Registration Number
- CTRI/2022/10/046317
- Lead Sponsor
- Dr Bipin Shaji
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients aged 18 years and above of both gender, diagnosed with Hypothyroidism with metabolic syndrome [based on Modified National Cholesterol Education Program Adult Treatment Panel III (Modified NCEP ATP III) criteria] will be enrolled in the study.
The study includes both Inpatients and Outpatients.
Exclusion Criteria
Pregnant women, Type I Diabetic Mellitus, and Cancer patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in the Health-Related Quality of life in Hypothyroid patients with metabolic syndromeTimepoint: Baseline, 6 months, 12 months
- Secondary Outcome Measures
Name Time Method Improvement in the Medication adherence and therapeutic outcomes, economic outcomesTimepoint: Baseline, 6 months, 12 months